^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    ER negative

    i
    Other names: ESR1, Era, ESR, NR3A1, ER, ER beta
    Entrez ID:
    2099
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    1d
    Improved polygenic risk prediction models for breast cancer subtypes in women of African ancestry. (PubMed, Nat Genet)
    These findings demonstrate markedly improved PRS accuracy for BC risk prediction in African-ancestry women. Using these PRS models for screening will help promote more equitable cancer prevention efforts.
    Journal
    |
    ER (Estrogen receptor)
    |
    ER positive • ER negative
    3d
    X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma (clinicaltrials.gov)
    P1, N=52, Recruiting, Immunolight, LLC | N=20 --> 52
    Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA (Breast cancer early onset)
    |
    HER-2 negative • ER negative
    |
    methoxsalen (X-PACT)
    3d
    Evaluating the prognostic significance of HIST1H4C in breast cancer: implications for neoadjuvant therapy. (PubMed, Sci Rep)
    Furthermore, high HIST1H4C expression before and after-treatment in our center or in database has a positively correlation with poor prognosis. HIST1H4C is the potential biomarker of neoadjuvant therapy and prognosis for breast cancer.
    Journal
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER negative
    3d
    Evaluation of the new European risk classification for endometrial carcinoma: a cohort study. (PubMed, Int J Gynecol Cancer)
    The ESGO-ESTRO-ESP 2025 classification re-assigns approximately one-tenth of patients, with a meaningful impact on adjuvant therapy. The rarity of estrogen receptor negativity limits its role in no-specific-molecular-profile stratification. Variation in lymph node involvement across molecular tumor categories highlights opportunities for individualized surgical staging.
    Journal
    |
    ER (Estrogen receptor)
    |
    ER positive • MSI-H/dMMR • ER negative
    4d
    Efficacy and Safety of Iparomlimab and Tuvonralimab Combined with Albumin-bound Paclitaxel and Lobaplatin as Neoadjuvant Therapy for Stage II-III Triple-negative Breast Cancer：A Prospective, Multicenter, Single-Arm Study (ChiCTR2500114072)
    P4, N=67, Not yet recruiting, The First Affiliated Hospital of Army Medical University; The First Affiliated Hospital of Army Medical University
    New P4 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 amplification • HER-2 negative • ER negative
    |
    albumin-bound paclitaxel • lobaplatin (D19466) • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    4d
    A Single-Arm, Multicenter Clinical Study of Eribulin Mesylate in Combination with Ivonescimab as First-Line Treatment for Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer (ChiCTR2600117652)
    P2, N=50, Not yet recruiting, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University; Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 negative • ER negative
    |
    Halaven (eribulin mesylate) • Yidafan (ivonescimab)
    4d
    A single-arm, multicenter, phase II clinical trial on sacituzumab tirumotecan with toripalimab in neoadjuvant therapy for triple-negative breast cancer (ChiCTR2600116626)
    P2, N=34, Not yet recruiting, Jiangxi Cancer Hospital; Jiangxi Cancer Hospital
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER negative
    |
    Loqtorzi (toripalimab-tpzi) • Jiataile (sacituzumab tirumotecan)
    4d
    A Phase II, Single-Arm Clinical Study of Goserelin Microspheres for Ovarian Function Preservation During Adjuvant Chemotherapy in Premenopausal Patients with Early Breast Cancer (ChiCTR2500113196)
    P2, N=25, Not yet recruiting, The Third Bethune Hospital of Jilin University; The Third Bethune Hospital of Jilin University
    New P2 trial
    |
    ER (Estrogen receptor)
    |
    ER negative
    |
    goserelin acetate
    4d
    Cadonilimab combined with gemcitabine plus carboplatin in metastatic triple-negative breast cancer: a single-arm, multicenter, phase II clinical study (ChiCTR2600117338)
    P2, N=38, Recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • ER negative
    |
    carboplatin • gemcitabine • Kaitanni (cadonilimab)
    4d
    A Phase I Dose-Escalation and Dose-Expansion Clinical Study Evaluating the Tolerability, Safety, Pharmacokinetics , and Efficacy of MT027 Cell Injection in Patients with Triple-Negative Breast Cancer and Brain Metastases (ChiCTR2600116792)
    P1, N=22, Not yet recruiting, Guangdong Provincial People's Hospital; Guangdong Provincial People's Hospital
    New P1 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CD276 (CD276 Molecule)
    |
    ER negative
    |
    MT027
    4d
    Preoperative Oral Dihydroartemisinin Triple-Negative Breast Cancer: A Single-Center, Open-Label, Single-Arm Pilot Study (ChiCTR2500102437)
    P=N/A, N=8, Recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center | Not yet recruiting --> Recruiting | Initiation date: May 2025 --> Oct 2025
    Enrollment open • Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • ER negative
    6d
    Classic Protocadherin PCDH10 Functions as a Tumor Suppressive Scaffold Protein Antagonizing Oncogenic WNT/β-catenin Signaling in Breast Carcinogenesis. (PubMed, Int J Biol Sci)
    PCDH10 restoration antagonizes tumorigenesis by dual blockade of Wnt/β-catenin and Akt signaling pathways through interactions with GSK-3β, β-catenin, and LMNA, as a scaffold protein. Our findings reveal a novel PCDH10-dependent tumor-suppressive axis and highlight its potential as a therapeutic target and biomarker in breast cancer.
    Journal
    |
    ER (Estrogen receptor) • LMNA (Lamin A/C) • RHOA (Ras homolog family member A) • CDH23 (Cadherin Related 23)
    |
    ER negative